{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266836","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.978054+00:00","generated_at":"2026-05-17T00:18:19.121545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials","bullets":["Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).","Cash, equivalents & securities $1.93B; full-year GAAP net loss guidance reaffirmed at $1.03B-$1.09B.","RASolute 302 (PDAC) enrollment winding down; data readout on track for 2026.","RASolute 304 (adjuvant PDAC) initiated; RASolute 303 (1L metastatic PDAC) expected to start this year.","New CDO Alan Sandler, U.S. GM Alicia Gardner, Europe GM Gerwin Winter appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266836","json":"https://secwatch.observer/filing/0001193125-25-266836.json","markdown":"https://secwatch.observer/filing/0001193125-25-266836.md","text":"https://secwatch.observer/filing/0001193125-25-266836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/0001193125-25-266836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/rvmd-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:19.121545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}